Research programme: natural killer T cell-based therapeutics - NKT TherapeuticsAlternative Names: iNKT mAb; NKTT 320
Latest Information Update: 20 Feb 2013
At a glance
- Originator NKT-Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Natural killer cell modulators; Natural killer cell receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Asthma; Atopic dermatitis; Autoimmune disorders; Cancer; Sickle cell anaemia